Scarica l'app Stockscreener
13.05
3.08%
0.39
Dopo l'orario di chiusura:
13.06
0.010
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com Nigeria
Viatris Inc. Stock Outperforms Market Despite Losses On The Day - 富途资讯
Viatris Launches Inpefa To Treat Heart Failure In UAE - Nasdaq
Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases - TradingView — Track All Markets
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - PR Newswire
Movement Recap: Is Viatris Inc backed by strong institutional buyingBear Alert & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy - Construction World India
Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Argus Research Upgrades Viatris (VTRS) - Nasdaq
Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues
Viatris stock tests multi-year ceiling after impressive rally - FXStreet
United States Treatment-Resistant Depression Market to grow - openPR.com
Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz
RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²
Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MSN
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.
What is the earnings history of Viatris IncWeekly Investment Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Viatris Stock: Is Wall Street Bullish or Bearish? - MSN
Viatris hits main goals in Phase 3 trial for birth control patch - MSN
Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target - Yahoo Finance
Viatris Inc.: Can a Hybrid Pharma Powerhouse Reinvent the Generic Drug Game? - AD HOC NEWS
Goldman Sachs Adjusts Price Target on Viatris to $13 From $12, Maintains Neutral Rating - marketscreener.com
Can Viatris Inc. stock deliver strong Q4 earningsTrend Reversal & Growth Focused Entry Point Reports - ulpravda.ru
How analysts revise price targets for Viatris Inc. (VIA) stockCPI Data & High Conviction Investment Ideas - ulpravda.ru
Does Viatris Inc. (VIA) stock trade below intrinsic value2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru
Viatris Inc. Stock Rises Thursday, Outperforms Market - 富途牛牛
Performance Recap: Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru
Viatris names veteran executive to lead people and corporate affairs - The Business Journals
Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa
Viatris stock hits 52-week high at 12.68 USD - Investing.com
Why Viatris Inc. stock remains on buy listsEarnings Trend Report & AI Powered Trade Plan Recommendations - ulpravda.ru
Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - marketscreener.com
Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia
Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris
Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS
Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves - MSN
Is Viatris stock outperforming the Dow? - MSN
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Taxanes Market to Reach US$ 8.67 Billion by 2032 at 10.73% CAGR; - openPR.com
1 Healthcare Stock to Target This Week and 2 We Turn Down - FinancialContent
A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones - Yahoo Finance
Anti-Depression Drugs Market to Reach USD 22.10 Billion by 2031 | - openPR.com
Viatris Inc.: Can a Hybrid Pharma Powerhouse Redefine Global Generics and Biosimilars? - AD HOC NEWS
Take Profit: Will Viatris Inc stock outperform Nasdaq indexJuly 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn
Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones - Finviz
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris stock hits 52-week high at $12.60 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $12.60 - Investing.com India
0.65%
9.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):